SWGC
GLUE icon

Summit Wealth Group (Colorado)’s Monte Rosa Therapeutics GLUE Stock Holding History

Summit Wealth Group (Colorado)’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,002
Closed -$311K – 333
2025
Q3 		$311K Buy
+2,002
New +$10.6K 0.05% 190

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Wealth Group (Colorado)'s GLUE Position: Q4 2025 in Review

Summit Wealth Group (Colorado) sold out of Monte Rosa Therapeutics (GLUE) in Q4 2025, closing a stake of 2,002 shares — an estimated $311K sold.

Summit Wealth Group (Colorado) first reported a position in GLUE in Q3 2025 and held it in 1 quarter. The position peaked at $311K in Q3 2025. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Summit Wealth Group (Colorado) reported no remaining Monte Rosa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Summit Wealth Group (Colorado) sold 2,002 Monte Rosa Therapeutics shares in Q4 2025, an estimated $311K.
  • Summit Wealth Group (Colorado) first reported a position in Monte Rosa Therapeutics in Q3 2025 and held it in 1 quarter.
  • Summit Wealth Group (Colorado)'s Monte Rosa Therapeutics position peaked at $311K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Summit Wealth Group (Colorado)'s 13F filing for Q4 2025, filed 4 Feb 2026.